Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 May 19;16(7):e009837. doi: 10.1161/CIRCHEARTFAILURE.122.009837

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 The Authors.

Circulation: Heart Failure is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited and is not used for commercial purposes.

PMC Copyright notice

Figure 2. — Effects of dapagliflozin vs placebo at 12 weeks on the Kansas City Cardiomyopathy Questionnaire–Clinical Summary Score (KCCQ-CSS) across demographic and clinical subgroups of interest. A, Effects on KCCQ-CSS across demographic and clinical subgroups of interest. B, Effects on KCCQ-CSS across the range of ejection fraction (ejection fraction modeled continuously with a restricted cubic spline; adjusted for baseline KCCQ-CSS, sex, type 2 diabetes status, atrial fibrillation [AF] type, and estimated glomerular filtration rate). LVEF indicates left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NT-proBNP, N-terminal pro-B-type natriuretic peptide; and NYHA, New York Heart Association.